A Case of Plasmablastic Lymphoma in an Immunocompetent Individual

Authors

  • Rekha Bansal DNB Resident, Department of Medical Oncology, Omega Hospitals, Hyderabad
  • P. Satya Dattatreya Senior Medical Oncologist, Omega Hospitals, Hyderabad, India

DOI:

https://doi.org/10.15379/2408-9877.2019.06.01.02

Keywords:

Plasmablastic lymphoma, Immunocompetent, Extraoral disease, Non-Hodgkin’s lymphomas, B-cell lymphoma

Abstract

Introduction: Plasmablastic Lymphoma, a subtype of Diffuse large B-cell lymphoma is known to occur in association with HIV infection. We report a case of extraoral plasmablastic lymphoma at an unusual site.

Case presentation: 66 years old male patient was evaluated in view of persistent headache and proptosis. He was found to have a frontal mass lesion extending into the orbit. Pathology and IHC confirmed it to be Plasmablastic Lymphoma. He received treatment with DA-R-EPOCH with bortezomib to which he responded extremely well and remains disease free for more than 12 months.

Conclusion: Despite being an aggressive lymphoma with poor prognosis, our patient responded extremely well to the treatment.

References

Stein H, Harris NL, Campo E. Plasmablastic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al. eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press. World Health Organization Classification of Tumours; 2008; 2: 256-257.

Thakral, Charu, et al. "Plasmablastic lymphoma in an immunocompetent patient." Journal of Clinical Oncology 2009; 27(25): e78-e81. https://doi.org/10.1200/JCO.2009.22.2208

Loghavi, Sanam, et al. "Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients." Journal of hematology & oncology 2015; 8(1): 65. https://doi.org/10.1186/s13045-015-0163-z

Castillo J, Pantanowitz L, Bezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol 2008; 83(10): 804-809 https://doi.org/10.1002/ajh.21250

Raviele PR, Pruneri G, Maiorano E. Plasmablastic lymphoma: a review. Oral Diseases 2009; 15: 38-45 https://doi.org/10.1111/j.1601-0825.2008.01493.x

Pruneri G, Graziadei G, Ermellino L, Baldini L, Neri A, Buffa R. Plasmablastic lymphoma of the stomach; a case report. Haematologica. 1998; 83(1): 87-89.

Folk GS, Abbondanzo SL, Childers EL, et al. Plasmablastic lymphoma: A clinicopathologic correlation. Ann Diagn Pathol 2006; 10: 8-12. https://doi.org/10.1016/j.anndiagpath.2005.07.009

Castillo, Jorge J., Michele Bibas, and Roberto N. Miranda. "The biology and treatment of plasmablastic lymphoma." Blood 2015; 125(15): 2323-2330. https://doi.org/10.1182/blood-2014-10-567479

Colomo L, Loong F, Rives S, Pittaluga S, Martinez A, Loopen-Guillermo A, Ojanguren J et al. Diffue large B-cell lymphoma with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol 2004; 28: 736-747 https://doi.org/10.1097/01.pas.0000126781.87158.e3

Scheper MA, Nikitakis NG, Fernandes R, Gocke CD, Ord RA, Sauk JJ. Oral plasmablastic lymphoma in an HIV-negative patient: a case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol 2005; 100: 198-206 https://doi.org/10.1016/j.tripleo.2004.11.050

Valenzuela AA, Walker NJ, Sullivan TJ. Plasmablastic lymphoma in the orbit: case report. Orbi 2008; 27: 227-229 https://doi.org/10.1080/01676830802014150

Castillo JJ, Winer ES, Stachurski D, et al. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma 2010; 51: 2047-2053. https://doi.org/10.3109/10428194.2010.516040

Morscio J, Dierickx D, Nijs J, et al. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. Am J Surg Pathol 2014; 38(7): 875-886. https://doi.org/10.1097/PAS.0000000000000234

LIu, MIn, et al. "Human immunodeficiency virus-negative plasmablastic lymphoma: A comprehensive analysis of 114 cases." Oncology reports 2015; 33(4): 1615-1620. https://doi.org/10.3892/or.2015.3808

Vega F, Chang CC, Medeiros LJ, et al. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol 2005; 18(6): 806-815 https://doi.org/10.1038/modpathol.3800355

Guidelines Version NCCN. 4. 2014. AIDS-Related B-Cell Lymphomas. http://www.nccn.org/ professionals/physician_gls/pdf/nhl.pdf. Accessed September 18, 2014.

Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 2008; 26(16): 2717-2724. https://doi.org/10.1200/JCO.2007.13.1391

Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14(3): 925-934. https://doi.org/10.1200/JCO.1996.14.3.925

Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer. 2002; 94(5): 1492-1499. https://doi.org/10.1002/cncr.10365

Castillo J, Pantanowitz L, Dezube BJ. HIV associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol 2008; 83(10): 804-809. https://doi.org/10.1002/ajh.21250

Castillo JJ, Winer ES, Stachurski D, et al. HIV negative plasmablastic lymphoma: not in the mouth. Clin Lymphoma Myeloma Leuk 2011; 11(2): 185-189. https://doi.org/10.1016/j.clml.2011.03.008

Castillo J, Pantanowitz L, Dezube BJ. HIV associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol 2008; 83(10): 804-809. https://doi.org/10.1002/ajh.21250

Castillo JJ, Winer ES, Stachurski D, et al. HIV negative plasmablastic lymphoma: not in the mouth. Clin Lymphoma Myeloma Leuk 2011; 11(2): 185-189. https://doi.org/10.1016/j.clml.2011.03.008

Klapproth K, Wirth T. Advances in the understanding of MYC-induced lymphomagenesis. Br J Haematol 2010; 149(4): 484-497. https://doi.org/10.1111/j.1365-2141.2010.08159.x

Simonitsch-Klupp I, Hauser I, Ott G, et al. Diffuse large B-cell lymphomas with plasmablastic plasmacytoid features are associated with TP53 deletions and poor clinical outcome. Leukemia 2004; 18(1): 146-155. https://doi.org/10.1038/sj.leu.2403206

Downloads

Published

2019-01-30

Issue

Vol. 6 No. 1 (2019)

Section

Articles

License

Policy for Journals/Articles with Open Access

Authors who publish with this journal agree to the following terms:
    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  1. Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work

Policy for Journals / Manuscript with Paid Access

Authors who publish with this journal agree to the following terms:
    1. Publisher retain copyright .

  1. Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .